|Bid||358.00 x 100|
|Ask||359.90 x 100|
|Day's Range||356.61 - 360.50|
|52 Week Range||249.17 - 370.57|
|PE Ratio (TTM)||25.64|
|Earnings Date||Jul 24, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||367.08|
CNBC's Dominic Chu reports on Sarissa Capital Management's Alex Denner presenting his best investment ideas at Delivering Alpha.
The search for a drug to treat Alzheimer's disease, the most common form of dementia, has been marked by clinical trial failures. The dementia scientists are worried that the history of failures has left the health-care system unprepared to diagnose and treat patients if a breakthrough Alzheimer's drug becomes available. Fifty million people worldwide and six million Americans are living with Alzheimer’s, and the number is expected to rise sharply.
Biogen (BIIB) today announced it will host a live webcast providing a Q&A session related to its Alzheimer’s disease investigational therapies on Wednesday, July 25, 2018. The live webcast will begin at 6:00 p.m. ET/5:00 p.m. CT on July 25, 2018, with Alfred Sandrock, Jr., M.D., Ph.D., executive vice president and chief medical officer at Biogen, and Samantha Budd Haeberlein, Ph.D., vice president, Alzheimer’s disease, dementia and movement disorders, late stage clinical development at Biogen. To access the live webcast, please go to the Investors section of Biogen’s website at www.biogen.com/investors. Following the live webcast, an archived version of the call will be available on the website.
It's time to temper the excitement around Biogen Inc. Leerink Partners analyst Geoffrey Porges warned the Cambridge, Mass.-based biotech company's shares could experience "tremendous volatility" ahead of the release of detailed results from Biogen's Alzheimer's drug BAN2401 at the Alzheimer's Association International Conference meeting in Chicago on Wednesday, July 25. Porges estimated that the stock could fall by $20 to $334 if results showed a marginal difference in cognitive decline, but could gain as much as $40 to $393 a share if the data show substantial decreases, he wrote in a note.
On CNBC's "Mad Money Lightning Round" , Jim Cramer said Biogen Inc (NASDAQ: BIIB ) could double if it meets its endpoints and it could lose 40 percent if it doesn't meet them. The company failed ...
LONDON, UK / ACCESSWIRE / July 20, 2018 / If you want access to our free research report on Biogen Inc. (NASDAQ: BIIB), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=BIIB as the Company’s latest news hit the wire. On July 18, 2018, the Company declared that it will present data from its Alzheimer’s disease clinical development portfolio at the upcoming Alzheimer’s Association International Conference (AAIC), to be held in Chicago on July 22-26, 2018. Active-Investors.com is currently working on the research report for Orgenesis Inc. (NASDAQ: ORGS), which also belongs to the Healthcare sector as the Company Biogen.
On the Q2 call, investor focus will be on the impact of Roche's newly launched drug, Ocrevus on Biogen's (BIIB) MS franchise and Spinraza's performance
The Delivering Alpha 2018 conference took place Wednesday in New York, and this year’s event included a number of Wall Street heavy-hitters. Benzinga Pro reported live from Delivering Alpha all day long, ...
Netflix failed to meet market expectations, posting disappointing subscriber adds and lowering third-quarter targets.
Celgene (NASDAQ:CELG) continues to struggle. A series of self-inflicted wounds and a looming patent expiration plague the Summit, New Jersey-based firm. As a result, CELG stock has lost more than 40% of its value since its October 2017 high.
President Trump's attack on large pharma companies over drug prices might have grabbed headlines recently, but that shouldn't distract from the firms and drugs that have been driving change and innovation in the biotech industry. Here's a rundown of some of the news from small to large companies in the past few weeks that could have a big impact on the biotechnology and pharmaceutical sectors. 1. Biogen's Alzheimer's drug trial results show promise Curing Alzheimer's disease has frustrated the healthcare industry for years after numerous failed attempts have been made to find a treatment, but Biogen Inc.
Sarissa Capital Management chief investment officer Alex Denner highlighted Biogen as one of his top stock picks Wednesday. Sarissa Capital Management chief investment officer Alex Denner highlighted Biogen BIIB as one of his top stock picks at the Delivering Alpha Conference in New York on Wednesday.
Ongoing Alzheimer`s disease research programs target possible causes of the disease through multiple modalities Data to be presented from Alzheimer`s disease clinical development portfolio including aducanumab, ...
Biogen (BIIB) announced it will present data from its Alzheimer’s disease clinical development portfolio at the upcoming Alzheimer’s Association International Conference (AAIC) in Chicago (July 22-26). Data being presented are part of Biogen’s research programs targeting several of the identified causes of Alzheimer’s disease, focusing on early-stage disease.
News of positive clinical data for its Alzheimer’s study lifted the entire biotechnology sector. Oddly enough, markets largely ignored pharmaceutical stocks, choosing instead to invest in the riskier biotech sector. The following are Big Pharma stocks that should be on the radar of most investors.
Celgene Corporation (NASDAQ:CELG) stock looks attractive here, for a number of reasons. Celgene stock has sold off, losing about 43% of its value. Celgene touched a four-year low in May before a recent rebound. The decline leaves Celgene looking awfully cheap, at a little over 8.3x 2019 consensus EPS estimates.
One successful drug on the market. Two potential approvals on the way. Six big partners. But do the numbers add up to buying Ionis right now?